-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on AbbVie, Raises Price Target to $295

Benzinga·11/02/2026 21:35:43
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $275 to $295.